-
1 Comment
Boryung Pharmaceutical Co., Ltd is currently in a long term uptrend where the price is trading 18.0% above its 200 day moving average.
From a valuation standpoint, the stock is 79.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.8.
Boryung Pharmaceutical Co., Ltd's total revenue sank by 0.4% to $138B since the same quarter in the previous year.
Its net income has dropped by 16.6% to $4B since the same quarter in the previous year.
Finally, its free cash flow fell by 60.1% to $-7B since the same quarter in the previous year.
Based on the above factors, Boryung Pharmaceutical Co., Ltd gets an overall score of 2/5.
| Sector | Healthcare |
|---|---|
| Industry | Drug Manufacturers - Specialty & Generic |
| Exchange | KO |
| CurrencyCode | KRW |
| ISIN | KR7003850005 |
| PE Ratio | None |
|---|---|
| Target Price | 15000 |
| Market Cap | 715B |
| Beta | 0.65 |
| Dividend Yield | 1.2% |
Boryung Corporation engages in the manufacture and sale of pharmaceutical products in South Korea and internationally. It offers prescription drugs for hypertension, dyslipidemia, diabetes, central nervous system, and oncology drugs. The company was formerly known as Boryung Pharmaceutical Co., Ltd. and changed its name to Boryung Corporation in March 2022. Boryung Corporation was founded in 1957 and is headquartered in Seoul, South Korea.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 003850.KO using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
